# OnCo record nct07318883 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07318883/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07318883", "NCT07318883" ;
  schema:name "A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab"@en ;
  schema:description "A phase 2/3 trial of serplulimab, pembrolizumab and carboplatin in lung cancer, run by Shanghai Henlius Biotech, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07318883/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07318883> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/henlius/> .